Magnoglia is a Monegasque company of prospection and development of innovative pharmaceutical products.

Magnoglia is particularly active in the fields of ophthalmology, rheumatology and more specifically neurology.

On the last specialty, Magnoglia is specialised in a 360° approach in the field of neurons and astrocytes, the main cells of the central nervous system.

Magnoglia’s goal is to highlight any product regarding neurodegenerative diseases as well as solutions for the improvement of brain faculties.


TRB Chemedica is a Swiss pharmaceutical SME focused on the research, development and marketing of niche innovating products in specific therapeutic fields such as rheumatology, ophthalmology and neurology. TRB Chemedica sells a range of ethical neurological products and medical devices, most of them licensed in over 60 countries around the world.

TRB Chemedica is a growing organisation that currently employs over 700 persons around the world. The registered office is located in Geneva, Switzerland with subsidiaries in Germany, Central America, Argentina, Austria, Brazil, France, Hong Kong, Hungary, Malaysia, Mexico, Poland, United Kingdom, Singapore, Switzerland, Thailand and a representative office in Russia. TRB Chemedica’s plan for the future is to increase its production capacity, continue to develop its subsidiaries and extend its distribution network in order to cover more countries around the world.